Senores Pharmaceuticals · NSE: SENORES · BSE: 544319
Q3 FY26 results · Oct–Dec 2025
Senores Pharmaceuticals reported revenue from operations of ₹174.56 crore (up 69.4% from Q3 FY25) and net profit of ₹33.58 crore (up 104.4% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 174.56 | 103.02 | +69.4% | 161.76 | +7.9% |
| Other income | 3.78 | 5.16 | −26.7% | 5.41 | −30.1% |
| Total income | 178.34 | 108.17 | +64.9% | 167.17 | +6.7% |
| Profit before tax | 44.60 | 20.48 | +117.7% | 40.64 | +9.7% |
| Net profit for the period | 33.58 | 16.43 | +104.4% | 30.12 | +11.5% |
| Attributable to shareholders of the company | 31.66 | 17.18 | +84.3% | 32.38 | −2.2% |
| EPS, basic (₹) | 7.29 | 5.04 | +44.7% | 6.54 | +11.5% |
| Net margin (%) | 19.2 | 15.9 | 18.6 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 28.76 | 9.59 | +199.9% | 35.33 | −18.6% |
| Other income | 9.78 | 7.19 | +36.1% | 11.36 | −13.9% |
| Total income | 38.54 | 16.78 | +129.7% | 46.69 | −17.5% |
| Profit before tax | 3.52 | 1.32 | +166.5% | 7.65 | −54.0% |
| Net profit for the period | 2.65 | 1.07 | +146.5% | 6.43 | −58.8% |
| EPS, basic (₹) | 1.98 | 0.32 | +524.6% | 1.40 | +41.4% |
| Net margin (%) | 9.2 | 11.2 | 18.2 |
Consolidated
- Filed with BSE
- 20 Jan 2026, 17:15 IST
- Board meeting
- 20 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Jan 2026, 17:15 IST
- Board meeting
- 20 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE